TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MSTR
Strategy
-- 304.000 AAPL
Apple
-- 218.270 
NEWS
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs
NanoViricides has signed a Memorandum of Understanding (MoU) with TheraCour Pharma, granting it a right of first refusal (ROFR) for all antiviral drug developments. This agreement, made on September 23, 2024, includes intellectual property rights for developing treatments against any viral infections.
The company's lead drug, NV-387, has shown promising results in animal studies against various viruses and is set to enter Phase II clinical trials for diseases like RSV, Influenza, Bird Flu, COVID, and MPOX/Smallpox. Additionally, the company has developed 'Trojan Horse' drugs that can target multiple stages of a virus's lifecycle.
This MoU allows NanoViricides to rapidly develop new antiviral drugs, even for unforeseen viruses, and negotiate licenses for specific antiviral fields. The nanoviricide technology aims to revolutionize antiviral treatments by mimicking host cells to destabilize viruses.
The company's lead drug, NV-387, has shown promising results in animal studies against various viruses and is set to enter Phase II clinical trials for diseases like RSV, Influenza, Bird Flu, COVID, and MPOX/Smallpox. Additionally, the company has developed 'Trojan Horse' drugs that can target multiple stages of a virus's lifecycle.
This MoU allows NanoViricides to rapidly develop new antiviral drugs, even for unforeseen viruses, and negotiate licenses for specific antiviral fields. The nanoviricide technology aims to revolutionize antiviral treatments by mimicking host cells to destabilize viruses.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment